Recro Pharma (NASDAQ:REPH) Lowered to Hold at ValuEngine

ValuEngine downgraded shares of Recro Pharma (NASDAQ:REPH) from a buy rating to a hold rating in a research note released on Tuesday morning, ValuEngine reports.

Several other research firms have also recently weighed in on REPH. Oppenheimer set a $20.00 price target on shares of Recro Pharma and gave the company a buy rating in a report on Friday, August 9th. Zacks Investment Research upgraded shares of Recro Pharma from a hold rating to a buy rating and set a $13.00 price target for the company in a report on Thursday, August 15th. Finally, BidaskClub cut shares of Recro Pharma from a strong-buy rating to a buy rating in a report on Saturday, August 31st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $12.70.

Shares of Recro Pharma stock traded up $0.41 on Tuesday, hitting $11.78. The company had a trading volume of 113,618 shares, compared to its average volume of 280,029. The firm has a market capitalization of $264.20 million, a P/E ratio of -4.73 and a beta of -0.50. Recro Pharma has a twelve month low of $5.53 and a twelve month high of $12.67. The stock has a 50-day moving average of $11.64 and a 200-day moving average of $9.81.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The company had revenue of $31.26 million during the quarter, compared to analyst estimates of $24.06 million. As a group, equities analysts predict that Recro Pharma will post -0.48 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in REPH. Bank of New York Mellon Corp lifted its position in shares of Recro Pharma by 1.7% in the second quarter. Bank of New York Mellon Corp now owns 58,297 shares of the specialty pharmaceutical company’s stock worth $593,000 after purchasing an additional 969 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Recro Pharma by 5.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 45,956 shares of the specialty pharmaceutical company’s stock worth $468,000 after purchasing an additional 2,510 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Recro Pharma in the second quarter worth $48,000. Bessemer Group Inc. bought a new stake in shares of Recro Pharma in the second quarter worth $57,000. Finally, Meeder Asset Management Inc. lifted its position in shares of Recro Pharma by 153.5% in the second quarter. Meeder Asset Management Inc. now owns 12,895 shares of the specialty pharmaceutical company’s stock worth $130,000 after purchasing an additional 7,809 shares in the last quarter. Institutional investors own 60.50% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Article: Are all No-Load Funds Equal?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.